Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cell Cycle Regulation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FZR1/Cdh1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FZR1 Recombinant Protein (WD40 Domain / Full Length) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View FZR1 Products |
| Gene Delivery | FZR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and cellular degradation assays. |
View FZR1 Products |
| Benchmark Ab | Anti-FZR1 Recombinant Antibody High-specificity positive control for Western Blot, IP, and IHC. |
View FZR1 Products |
| Validator | FZR1 siRNA Set For knockdown verification and specificity profiling. |
View FZR1 Products |
| Related Target A | CDC20 Homologous APC/C co-activator; essential for off-target and selectivity screening. |
View CDC20 Products |
| Related Target B | PLK1 Key downstream substrate of APC/C-Cdh1; utilized as a pharmacodynamic marker. |
View PLK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over CDC20 (WD40 domain homology) | Human FZR1 and CDC20 ortholog proteins available with >95% purity for comparative SPR/BLI profiling. |
| Intracellular target validation & knockdown | Sequence-verified siRNA pools and high-titer Lentiviral particles for stable cell line generation. |
| Lack of Controls | Recombinant Benchmark Antibodies included for expression and localization verification. |
| False Positives | Strictly verified mass-spectrometry QC profiles to ensure batch-to-batch structural consistency. |
Live FZR1/Cdh1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FZR1/Cdh1 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum mitotic inhibitors to targeted APC/C-Cdh1 modulators and PROTACs. As first-generation cell cycle therapies reach the clinic, the next wave of R&D is targeting the precise disruption of FZR1-substrate interactions to induce selective mitotic catastrophe in BRCA-mutant or HR-deficient solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Solid Tumors, Hematological Malignancies | Selectivity Assay (Need High-Purity FZR1 vs CDC20 Proteins) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Pioneers | Breast Cancer, Ovarian Cancer | Ternary Complex Validation (Need Sequence-Verified FZR1 and Substrates) |
| Gene Therapy / siRNA | RNAi Therapeutics Developers | Refractory Glioblastoma, Neurodegenerative Diseases | In vitro Knockdown Verification (Need Validated siRNA and Lentivirus) |